COPD Drugs Market in China 2016-2020 - Product Image

COPD Drugs Market in China 2016-2020

  • ID: 3769322
  • Report
  • Region: China
  • 74 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Almirall
  • AstraZeneca
  • Gilead Sciences
  • Mereo BioPharma Group
  • Orion
  • Theravance Biopharma
  • MORE
About the Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China

Chronic obstructive pulmonary disease (COPD) is a broad term that covers progressive lung diseases, including emphysema, chronic bronchitis, refractory (non-reversible) asthma, and some forms of bronchiectasis. It restricts airflow in the lungs and is characterized by diffculty breathing. The exact etiology of COPD is not understood, but most cases are caused due to genetic factors and by inhaling pollutants, including smoke, fumes, and chemicals. As the disease develops, the symptoms tend to get worse and damages the lungs. The disease cannot be cured, and can only be managed and treated.

The COPD drugs market in China is under penetrated. It is dominated by fixed dose combinations of LABA/ICS. Air pollution is the major contributing factor for the growing prevalence of the disease. Nearly 10% of the population in the region who are over the age of 40 years has COPD. The disease is expected to become one of the leading causes of death in the country by 2020. Lack of awareness about the disease and its treatment options affects the growth of the market in this region.

The analysts forecast the chronic obstructive pulmonary disease drugs market in China to grow at a CAGR of 15.56% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the chronic obstructive pulmonary disease drugs market in China for 2016-2020. To calculate the market size, the analyst considers the revenue generated from the total consumption of the chronic obstructive pulmonary disease drugs globally. The report does not include revenue generated from the aftermarket service of the product.

The market is divided into the following segments based on drug class:

- Bronchodilators
- Phosphodiesterase-4 (PDE-4) inhibitors
- Steroids
- Combination therapies

The report, Chronic Obstructive Pulmonary Disease (COPD) Drugs Market in China 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- Boehringer Ingelheim
- GSK
- Merck
- Novartis
Other prominent vendors
- Ache Laboratorios Farmaceuticos
- Almirall
- Aquinox Pharmaceuticals
- Ario Pharma
- BioMarck Pharmaceuticals
- Gilead Sciences
- Mereo BioPharma Group
- Mylan
- Orion
- Pearl Therapeutics
- Prosonix
- Teva Pharmaceutical Industry
- Theravance Biopharma
- Theron Pharmaceuticals
- Verona Pharma
- Xention
- ZAI Lab

Market drivers
- Increase in environmental pollution

Market challenges
- Low diagnosis rate

Market trends
- Increased focus on combination therapies

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Almirall
  • AstraZeneca
  • Gilead Sciences
  • Mereo BioPharma Group
  • Orion
  • Theravance Biopharma
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: COPD: An overview
  • Causes and risk factors
  • Symptoms
  • Diagnosis
  • Management
PART 06: China-Country snapshot
  • Social and economic conditions
  • Healthcare reform
  • Healthcare infrastructure
PART 07: Pharmaceutical industry in China
  • Market overview
  • Major pharmaceutical vendors in China
  • Opportunities for global and local vendors
  • Drug approval process in China
PART 08: Drug pricing and reimbursement
  • Market-driven drug pricing strategy
  • Scrutinization of illegal pricing of drugs
PART 09: Pipeline portfolio

PART 10: Global respiratory drugs market
  • Market overview
  • Global COPD drugs market
PART 11: Market landscape
  • COPD drugs market in china
  • Five forces analysis
PART 12: Market segmentation by drug class
  • Bronchodilators
  • PDE-4 inhibitors
  • Steroids
  • Combination therapies
  • Other medications
PART 13: Market drivers
  • Increase in prevalence of smoking
  • Rise in healthcare expenditure
  • Increase in environmental pollution
PART 14: Impact of drivers

PART 15: Market challenges
  • Low diagnosis rate
  • Alternative therapies
  • High cost of therapy
PART 16: Impact of drivers and challenges

PART 17: Market trends
  • Rise in awareness programs
  • Increased focus on combination therapies
  • Rise in R&D by global companies
PART 18: Vendor landscape
  • Competitive scenario
  • AstraZeneca
  • Boehringer Ingelheim
  • GSK
  • Merck
  • Novartis
  • Other prominent vendors
PART 19: Appendix
  • List of abbreviations
PART 20: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: China GDP 2010-2014 ($ trillions)
Exhibit 03: Healthcare expenditure 2009-2013 (% of GDP)
Exhibit 04: Healthcare reforms in China
Exhibit 05: Pharmaceutical market in China 2015-2020 ($ billions)
Exhibit 06: Some top domestic and international vendors operating in China
Exhibit 07: China pharmaceutical market overview: SWOT analysis
Exhibit 08: New drug approval (NDA) review process in China
Exhibit 09: New drug approval process in China
Exhibit 10: Drug registration classification and requirements in China
Exhibit 11: Changes in drug pricing system before and after 2015 reforms
Exhibit 12: Pipeline portfolio: COPD drugs
Exhibit 13: Global respiratory drugs market 2015-2020 ($ billions)
Exhibit 14: Global respiratory drugs market shares by type of disease 2015
Exhibit 15: Global COPD drugs market 2015-2020 ($ billions)
Exhibit 16: Key drivers and challenges in global COPD drugs market
Exhibit 17: Global COPD drugs market by class of drugs 2015
Exhibit 18: COPD drugs in China in global respiratory drugs market 2015
Exhibit 19: COPD drugs market in China 2015-2020 ($ billions)
Exhibit 20: Five forces analysis
Exhibit 21: Segmentation of COPD drugs based on drug class
Exhibit 22: Healthcare spending in China 2004-2014
Exhibit 23: Impact of drivers
Exhibit 24: Impact of drivers and challenges
Exhibit 25: AstraZeneca: YoY revenue and growth rate of Symbicort in China 2014-2015 ($ millions)
Exhibit 26: AstraZeneca: YoY revenue and growth rate of Symbicort in emerging markets 2013-2015 ($ millions)
Exhibit 27: AstraZeneca: YoY revenue and growth rate of Pulmicort in China 2014-2015 ($ millions)
Exhibit 28: AstraZeneca: YoY revenue and growth rate of Pulmicort in emerging markets 2013-2015 ($ millions)
Exhibit 29: AstraZeneca: Key takeaways
Exhibit 30: Boehringer Ingelheim: Key takeaways
Exhibit 31: GSK: YoY revenue and growth rate of Seretide/Advair in international markets 2014-2015 ($ billions)
Exhibit 32: GSK: YoY revenue and growth rate of Flixotide/Flovent in international markets 2014-2015 ($ millions)
Exhibit 33: GSK: YoY revenue and growth rate of Ventolin in international markets 2014-2015 ($ millions)
Exhibit 34: GSK: YoY growth and revenue of Relvar/Breo Ellipta in international markets 2014-2015 ($ millions)
Exhibit 35: GSK: Key takeaways
Exhibit 36: Merck: Key takeaways
Exhibit 37: Novartis: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Almirall
  • AstraZeneca
  • Gilead Sciences
  • Mereo BioPharma Group
  • Orion
  • Theravance Biopharma
  • MORE
New Report Released: - COPD Drugs Market in China 2016-2020

The author of the report recognizes the following companies as the key players in the COPD drugs market in China: AstraZeneca, Boehringer Ingelheim, GSK, Merck, and Novartis.

Other Prominent Vendors in the market are: Ache Laboratorios Farmaceuticos, Almirall, Aquinox Pharmaceuticals, Ario Pharma, BioMarck Pharmaceuticals, Gilead Sciences, Mereo BioPharma Group, Mylan, Orion, Pearl Therapeutics, Prosonix, Teva Pharmaceutical Industry, Theravance Biopharma, Theron Pharmaceuticals, Verona Pharma, Xention, and ZAI Lab.

Commenting on the report, an analyst from the research team said: “A key trend which is boosting market growth is the increased focus on combination therapies. Combination therapies have a better advantage over monotherapies in providing better efficacy in the treatment of a condition. Manufacturers are now concentrating on developing combination therapies to treat COPD.These combination therapies reduce COPD-related hospitalizations and bring out better treatment outcomes in patients. Thus, the development of combinations therapies will increase the patient compliance toward the uptake of medications and help in the growth of the market.”

According to the report, pollutants such as ground-level ozone, carbon dioxide, smog, fumes from vehicles, and particulates such as dust, soot, and pollen grains are known to trigger diseases such as COPD, asthma, bronchitis, and other respiratory issues. Airborne particles, sulfur dioxide, and nitrogen oxide are critical environment pollutants that worsen respiratory symptoms. Rapid globalization, urbanization, and industrialization have led to the rise in environmental pollution, which has increased the prevalence of COPD.

Further, the report states that a major factor that could hamper market growth is the low diagnosis rate of COPD. It is difficult for physicians to recognize COPD at an early stage as the first symptoms of the disease include common problems such as a cough, sputum production, and shortness of breath. Thus, the diagnosis rate is only about one-third of the prevalent cases. This low diagnosis of COPD can be attributed to the lack of physician’s awareness about the risk factors, symptoms, and biomarkers of the disease.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AstraZeneca
- Boehringer Ingelheim
- GSK
- Merck
- Novartis
- Ache Laboratorios Farmaceuticos
- Almirall
- Aquinox Pharmaceuticals
- Ario Pharma
- BioMarck Pharmaceuticals
- Gilead Sciences
- Mereo BioPharma Group
- Mylan
- Orion
- Pearl Therapeutics
- Prosonix
- Teva Pharmaceutical Industry
- Theravance Biopharma
- Theron Pharmaceuticals
- Verona Pharma
- Xention
- ZAI Lab.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll